Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Aug 12;18(5):251-60.
doi: 10.1016/j.rpor.2013.06.005.

Tamoxifen in breast cancer ipse dixit in uterine malignant mixed Müllerian tumor and sarcoma-A report of 8 cases and review of the literature

Ana Luisa Cardoso Vasconcelos  1 , Beatriz Nunes  1 , Catarina Duarte  1 , Vera Mendonça  1 , Joana Ribeiro  2 , Marília Jorge  1 , Isabel Monteiro Grillo  3
Affiliations
Review

Tamoxifen in breast cancer ipse dixit in uterine malignant mixed Müllerian tumor and sarcoma-A report of 8 cases and review of the literature

Ana Luisa Cardoso Vasconcelos et al. Rep Pract Oncol Radiother. .

Abstract

Aim: Report the outcome of 8 patients (pts) with breast cancer (BC) treated with Tamoxifen (TAM) that developed malignant mixed Müllerian tumor (MMMT) and rare uterine sarcoma (RUS).

Patients and methods: Retrospective study based on data collected from the department medical records between April 1999 and September 2010 among 583 pts with endometrial cancer, 36 pts with MMMT and RUS histopathology. Among them, 8 pts underwent TAM between 4 and 10 years due to a previous diagnosis of BC; all pts were post-menopausal with regular gynecological surveillance; 6 pts (75%) with abnormal uterine bleeding. The diagnosis of 6 pts (MMMT) and 2 pts (RUS) occurred at median interval of 8 years (range 4-12) after initial BC treatment. Pts underwent surgical treatment and were staged as stage I (3pts), IIIA (3pts) and IIIC (2 pts) (FIGO 1988); followed by whole pelvis irradiation (50 Gy) and intracavitary HDR brachytherapy boost (24 Gy). Two pts underwent chemotherapy (CT). Overall and disease free survival was calculated by Kaplan Meier method.

Results: With a median follow-up of 47 months (range 17-130), 3 pts remain alive recurrence-free of BC and RUS. Four pts died with distant metastasis within the first follow-up year, without BC. One pt died from non-related cancer cause. No evidence of local recurrence was found in the whole group of pts. At two years, DFS and OS were 40% and 80%, respectively.

Conclusion: As reported in the literature, TAM administration and causal effect on MMMT and RUS in BC pts is still unknown. No reports about outcome from these specific pts were found.

Keywords: Breast cancer; Pelvic irradiation; Tamoxifen-related uterine sarcoma.

PubMed Disclaimer

Figures

Graph 1
Graph 1
Disease-free survival (Kaplan Meier curves on this group of patients with uterine sarcomas after BC).
Graph 2
Graph 2
Overall survival (Kaplan Meier curves on this group of patients with uterine sarcomas after BC).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ferlay J., Shin H.-R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–2917. - PubMed
    1. Fisher B., Dignam J., Wolmark N. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial. Lancet. 1999;353(June (9169)):1993–2000. - PubMed
    1. Fisher B., Costantino J.P., Wickerham D.L. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(September (18)):1371–1388. - PubMed
    1. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet. 1998;351(May (9114)):1451–1467. [editorial] - PubMed
    1. Zaloudek C., Norris H.J. Mesenchymal tumors of the uterus. In: Kurman R.J., editor. Blaustein's: pathology of the female genital tract. Springer-Verlag; New York: 1987. pp. 398–401.